Drug Profile
LCL 161
Alternative Names: LCL-161; NVP-LCL161; Second Mitochondria-derived Activator of Caspases (SMAC) mimetic - Novartis Oncology; SMAC mimetic LCL161Latest Information Update: 16 Jun 2022
Price :
$50
*
At a glance
- Originator Novartis
- Developer Mayo Clinic; National Cancer Institute (USA); Novartis; Novartis Oncology; SCRI Development Innovations; US Oncology Research
- Class Antineoplastics; Small molecules
- Mechanism of Action Inhibitor of apoptosis protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Multiple myeloma; Myelofibrosis; Triple negative breast cancer
- Phase I/II Ovarian cancer; Small cell lung cancer
- No development reported Pancreatic cancer; Solid tumours
Most Recent Events
- 19 May 2022 M.D. Anderson Cancer Center in collaboration with National Cancer Institute and Novartis Pharmaceuticals completes a phase II trials in Myelofibrosis (Monotherapy) in USA (PO) (NCT02098161)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (PO)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands (PO)